Ignite Creation Date:
2025-12-25 @ 4:12 AM
Ignite Modification Date:
2026-03-02 @ 10:36 PM
Study NCT ID:
NCT00486720
Status:
TERMINATED
Last Update Posted:
2015-07-03
First Post:
2007-06-14
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase IIa Vorinostat (MK0683, Suberoylanilide Hydroxamic Acid (SAHA)) Study in Lower Risk Myelodysplastic Syndromes (0683-064)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2007-06
Start Date Type:
None
Primary Completion Date:
2009-07
Primary Completion Date Type:
ACTUAL
Completion Date:
2009-07
Completion Date Type:
ACTUAL
First Submit Date:
2007-06-14
First Submit QC Date:
None
Study First Post Date:
2007-06-15
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2010-04-19
Results First Submit QC Date:
None
Results First Post Date:
2010-06-22
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2015-06-08
Last Update Post Date:
2015-07-03
Last Update Post Date Type:
ESTIMATED